Clinical Trial Update: PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML [Phase 1]

View source ↗

Summary

This is a Phase 1 study evaluating pegylated interferon alfa-2b in combination with low-dose cytarabine for early-phase chronic myeloid leukemia; the trial has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myeloid Leukemia | Phase 1 | Status: COMPLETED